Glioblastoma (GBM) is the most common and malignant primary brain tumor in adults.
Currently, the standard treatment of glioblastoma includes surgery, radiotherapy, and …

Cancer immunotherapy by immune checkpoint blockade has proven its great potential by
saving the lives of a proportion of late stage patients with immunogenic tumor types …

Tumor-associated macrophages (TAMs) play an important role in the immune response to
cancer, but the mechanisms by which the tumor microenvironment controls TAMs and T cell …

In many aggressive cancers, such as glioblastoma multiforme, progression is enabled by
local immunosuppression driven by the accumulation of regulatory T cells (Treg) and …

Temozolomide is the most widely used chemotherapy for patients with glioblastoma (GBM)
despite the fact that approximately half of treated patients have temozolomide resistance …

Glioblastomas (GBM) are the most frequent and aggressive malignant primary brain tumor
and remains a therapeutic challenge: even after multimodal therapy, median survival of …

The promise of dendritic cell (DC)–based immunotherapy has been established by two
decades of translational research. Of the four malignancies most targeted with clinical DC …

The central nervous system (CNS) possesses powerful local and global immunosuppressive
capabilities that modulate unwanted inflammatory reactions in nervous tissue. These same …

Purpose: Immunotherapeutic treatment strategies for glioblastoma (GBM) are under
investigation in clinical trials. However, our understanding of the immune phenotype of GBM …

Glioblastoma (GBM) is the most aggressive malignant primary brain tumor in adults, with a
median survival of 14.6 months. Recent efforts have focused on identifying clinically relevant …